Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416

Journal of Clinical Oncology

Volumn 21, Issue 11, 2003, Pages 2192-2198

  Kuenen, B C ^a   Levi, M ^a   Meijers, J C M ^a   Van Hinsbergh, V W M ^a   Berkhof, J ^a   Kakkar, A K ^a   Hoekman, K ^a   Pinedo, H M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN ANTAGONIST; CISPLATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GEMCITABINE; MARKER; SEMAXANIB; THROMBIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; ENDOTHELIAL CELL GROWTH FACTOR; INDOLE DERIVATIVE; LYMPHOKINE; PYRROLE DERIVATIVE; SIGNAL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; BLOOD CLOTTING; BLOOD VESSEL WALL; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOEMBOLISM; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; REGRESSION ANALYSIS; THROMBOCYTE; VASCULAR ENDOTHELIUM;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CISPLATIN; DEOXYCYTIDINE; E-SELECTIN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INDOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; PYRROLES; REGRESSION ANALYSIS; THROMBOEMBOLISM; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037530506     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.046     Document Type: Article

References (29)

1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
2. Levitzki A: Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82:231-239, 1999
3. Mendel DB, Laird AD, Smolich BD, et al: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15:29-41, 2000
4. Itokawa T, Nokihara H, Nishioka Y, et al: Antiangiogenic effect by SU5416 is partly attributable to inhibition of flt-1 receptor signaling. Mol Cancer Ther 1:295-302, 2002
5. Mendel DB, Schreck RE, West DC, et al: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6:4848-4858, 2000
6. Kuenen BC, Rosen L, Smit EF, et al: Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 20:1657-1667, 2002
7. Kuenen BC, Levi M, Meijers JCM, et al: Analysis of the coagulation cascade and endothelial cell activation during inhibition of the VEGF/VEGF-receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 22:1500-1505, 2002
8. Wielders S, Mukherjee M, Michiels J, et al: The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. Thromb Haemost 77:629-636, 1997
9. Cejka J: Performance characteristics of a commercial kit for assay of factor VIII-related antigen. Clin Chem 30:814-815, 1984
10. Laird NM, Ware JH: Random-effects models for longitudinal data. Biometrics 38:963-974, 1982
11. Goldstein H, Rasbash J, Plewis I, et al: A User's Guide to MLwiN. London, United Kingdom, Institute of Education, University of London, 1998
12. Verheul HM, Hoekman K, Luykx-de Bakker S, et al: Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187-2190, 1997
13. Benjamin LE: The controls of microvascular survival. Cancer Metastasis Rev 19:75-81, 2000
14. Togna GI, Togna AR, Franconi M, et al: Cisplatin triggers platelet activation. Thromb Res 99:503-509, 2000
15. Sodhi A, Pai K: Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers. Immunol Lett 34:183-188, 1992
16. Gan XH, Jewett A, Bonavida B: Activation of human peripheral-blood- derived monocytes by cis-diamminedichloroplatinum: Enhanced tumoricidal activity and secretion of tumor necrosis factor-alpha. Nat Immun 11:144-155, 1992
17. Verheul HM, Hoekman K, Lupu F, et al: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6:166-171, 2000
18. Gimbrone MA Jr, Aster RH, Cotran RS, et al: Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium. Nature 221:33-36, 1969
19. Pinedo HM, Verheul HM, D'Amato RJ, et al: Involvement of platelets in tumour angiogenesis? Lancet 352:1775-1777, 1998
20. Verheul HM, Jorna AS, Hoekman K, et al: Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96:4216-4221, 2000
21. Kuharsky AL, Fogelson AL: Surface-mediated control of blood coagulation: The role of binding site densities and platelet deposition. Biophys J 80:1050-1074, 2001
22. Diamond SL: Reaction complexity of flowing human blood. Biophys J 80:1031-1032, 2001
23. Kroep JR, Peters GJ, van Moorsel CJ, et al: Gemcitabine-cisplatin: A schedule finding study. Ann Oncol 10:1503-1510, 1999
24. Shepro D: The American Microcirculatory Society Landis Award lecture: Endothelial cells, inflammatory edema, and the microvascular barrier-Comments by a "free radical." Microvasc Res 35:246-264, 1988
25. Selheim F, Holmsen H, Vassbotn FS: Identification of functional VEGF receptors on human platelets. FEBS Lett 512:107-110, 2002
26. Rosen PJ, Amado R, Hecht JR, et al: A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 19:3a, 2000 (abstr 5D)
27. Rothenberg M, Berlin J, Cropp G, et al: Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 20:75a, 2001 (abstr 298)
28. Overmoyer B, Robertson K, Persons M, et al: A phase I pharmacokinetic and pharmacodynamic study of SU5416 and doxorubicin (ADR) in inflammatory breast cancer (IBC). Proc Am Soc Clin Oncol 20:99a, 2001 (abstr 391)
29. Rosen P, Kabbinavar F, Figlin R, et al: A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin. Proc Am Soc Clin Oncol 20:98a, 2001 (abstr 389)